Lantheus Holdings’ Much Awaited Share Repurchase Plan – Buyback Wednesdays

Amidst a flurry of earnings reports this month, one company caught my attention with a stock chart full of drama — sharp spikes and steep drops. In July, its share price soared, only to plummet 26% in early November in response to its third-quarter results.

The twist? The company posted solid numbers. Then came the game-changer: a $250 million share buyback (4.2% of its market cap), reigniting investor interes. Intrigued by these market moves, I decided to dive deeper into this company and its operations.

Source: InsideArbitrage

Lantheus Holdings, Inc. (LNTH) is a radiopharmaceutical leader with a robust portfolio that spans both diagnostics and therapeutics. The company’s products allow physicians to accurately diagnose and effectively treat conditions with targeted radiopharmaceuticals. These radiopharmaceuticals are medical compounds that combine a radioactive isotope with a pharmaceutical agent and are primarily used for diagnostic imaging and therapeutic applications.

Lantheus Holdings, Inc. (LNTH): $88.51

Market Cap: $6.15B

EV: $5.91B

Key Insights

• Lantheus achieved a record $1.3 billion in revenue for 2023, a 39% year-over-year increase driven by strong growth in its flagship products, PYLARIFY (+61%) and DEFINITY (+14%).
• PYLARIFY, accounting for 70% of total revenue, is poised to exceed $1 billion in sales by 2024, holding a dominant 65% market share despite competition. 
• With a strong balance sheet and robust free cash flow, Lantheus is strategically expanding its pipeline. 

Only plus or premium subscribers can access this post. Subscribe today.